Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Staphylococcal Infections | 21 | 2023 | 553 | 7.950 |
Why?
|
| Staphylococcus aureus | 20 | 2023 | 455 | 4.870 |
Why?
|
| Osteomyelitis | 9 | 2024 | 204 | 4.280 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 10 | 2023 | 220 | 3.740 |
Why?
|
| Streptococcal Infections | 6 | 2024 | 244 | 3.570 |
Why?
|
| Bacteremia | 11 | 2023 | 405 | 3.100 |
Why?
|
| Anti-Bacterial Agents | 22 | 2024 | 2398 | 2.360 |
Why?
|
| Arthritis, Infectious | 4 | 2021 | 59 | 2.010 |
Why?
|
| Sinusitis | 3 | 2024 | 117 | 1.740 |
Why?
|
| Streptococcus anginosus | 2 | 2024 | 9 | 1.590 |
Why?
|
| Otitis Media | 2 | 2024 | 82 | 1.520 |
Why?
|
| Microbial Sensitivity Tests | 13 | 2023 | 782 | 1.460 |
Why?
|
| Soft Tissue Infections | 4 | 2023 | 83 | 1.420 |
Why?
|
| Vancomycin | 4 | 2023 | 218 | 1.220 |
Why?
|
| Child | 34 | 2024 | 24262 | 1.060 |
Why?
|
| Pneumococcal Infections | 2 | 2021 | 274 | 0.910 |
Why?
|
| Haemophilus Infections | 2 | 2021 | 91 | 0.890 |
Why?
|
| Haemophilus influenzae | 2 | 2021 | 130 | 0.890 |
Why?
|
| Mastoiditis | 1 | 2024 | 31 | 0.890 |
Why?
|
| Texas | 12 | 2024 | 3558 | 0.860 |
Why?
|
| Brain Abscess | 1 | 2024 | 57 | 0.860 |
Why?
|
| Anti-Infective Agents | 3 | 2023 | 266 | 0.820 |
Why?
|
| Mupirocin | 2 | 2014 | 19 | 0.820 |
Why?
|
| Ascaridoidea | 1 | 2022 | 6 | 0.820 |
Why?
|
| Ascaridida Infections | 1 | 2022 | 6 | 0.820 |
Why?
|
| Child, Preschool | 19 | 2024 | 13927 | 0.800 |
Why?
|
| Anti-Infective Agents, Local | 3 | 2019 | 69 | 0.800 |
Why?
|
| Meningitis | 1 | 2022 | 98 | 0.780 |
Why?
|
| Pandemics | 3 | 2024 | 1100 | 0.750 |
Why?
|
| Endocarditis, Bacterial | 2 | 2021 | 129 | 0.720 |
Why?
|
| Streptococcus pyogenes | 3 | 2024 | 77 | 0.720 |
Why?
|
| Cefazolin | 1 | 2020 | 20 | 0.710 |
Why?
|
| Blood Culture | 1 | 2020 | 30 | 0.710 |
Why?
|
| Infant | 16 | 2024 | 12370 | 0.700 |
Why?
|
| Bacteria | 2 | 2021 | 484 | 0.690 |
Why?
|
| Thyroid Crisis | 1 | 2019 | 5 | 0.670 |
Why?
|
| Thyroiditis, Suppurative | 1 | 2019 | 5 | 0.670 |
Why?
|
| Candida tropicalis | 1 | 2019 | 16 | 0.660 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2022 | 862 | 0.650 |
Why?
|
| Community-Acquired Infections | 3 | 2021 | 240 | 0.640 |
Why?
|
| Retrospective Studies | 16 | 2024 | 16081 | 0.610 |
Why?
|
| Hospitalization | 3 | 2021 | 1737 | 0.610 |
Why?
|
| Bone Diseases, Infectious | 1 | 2018 | 8 | 0.610 |
Why?
|
| Candidiasis | 1 | 2019 | 129 | 0.610 |
Why?
|
| Humans | 41 | 2024 | 123280 | 0.610 |
Why?
|
| Disease Management | 2 | 2021 | 516 | 0.600 |
Why?
|
| Chlorhexidine | 2 | 2017 | 45 | 0.590 |
Why?
|
| Bacterial Typing Techniques | 3 | 2021 | 103 | 0.550 |
Why?
|
| Incidence | 6 | 2024 | 3055 | 0.500 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 365 | 0.490 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2014 | 133 | 0.470 |
Why?
|
| Male | 23 | 2024 | 60345 | 0.470 |
Why?
|
| Adolescent | 14 | 2024 | 19126 | 0.450 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2014 | 39 | 0.450 |
Why?
|
| Streptococcus pneumoniae | 2 | 2021 | 372 | 0.430 |
Why?
|
| Organ Transplantation | 1 | 2015 | 162 | 0.410 |
Why?
|
| Hospitals, Pediatric | 4 | 2019 | 781 | 0.400 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 805 | 0.400 |
Why?
|
| Multilocus Sequence Typing | 2 | 2023 | 56 | 0.400 |
Why?
|
| Methicillin | 2 | 2023 | 43 | 0.390 |
Why?
|
| Female | 20 | 2024 | 65628 | 0.370 |
Why?
|
| HIV Infections | 2 | 2012 | 1860 | 0.350 |
Why?
|
| Tertiary Care Centers | 2 | 2021 | 235 | 0.340 |
Why?
|
| Urinary Bladder Diseases | 1 | 2008 | 35 | 0.300 |
Why?
|
| Clindamycin | 2 | 2022 | 40 | 0.300 |
Why?
|
| Urology | 1 | 2008 | 74 | 0.280 |
Why?
|
| Adenoma | 1 | 2008 | 134 | 0.270 |
Why?
|
| Prospective Studies | 5 | 2024 | 6033 | 0.260 |
Why?
|
| Acute Disease | 3 | 2024 | 1093 | 0.260 |
Why?
|
| Abscess | 2 | 2024 | 138 | 0.240 |
Why?
|
| Penicillins | 2 | 2023 | 154 | 0.240 |
Why?
|
| Cephalosporins | 2 | 2022 | 138 | 0.230 |
Why?
|
| Hospitals | 2 | 2022 | 392 | 0.230 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 429 | 0.220 |
Why?
|
| Cross Infection | 2 | 2019 | 330 | 0.220 |
Why?
|
| Drug Administration Schedule | 2 | 2021 | 726 | 0.210 |
Why?
|
| Staphylococcal Skin Infections | 2 | 2014 | 37 | 0.200 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 5061 | 0.190 |
Why?
|
| Comorbidity | 3 | 2014 | 1497 | 0.190 |
Why?
|
| Treatment Outcome | 4 | 2021 | 12176 | 0.190 |
Why?
|
| Kingella | 1 | 2021 | 1 | 0.190 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2021 | 46 | 0.180 |
Why?
|
| Administration, Intravenous | 1 | 2021 | 143 | 0.180 |
Why?
|
| Metagenomics | 1 | 2022 | 109 | 0.180 |
Why?
|
| Ceftriaxone | 1 | 2021 | 68 | 0.180 |
Why?
|
| Streptococcus agalactiae | 1 | 2021 | 105 | 0.180 |
Why?
|
| Pott Puffy Tumor | 1 | 2020 | 3 | 0.170 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 37 | 0.170 |
Why?
|
| Central Nervous System Infections | 1 | 2020 | 21 | 0.170 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2019 | 92 | 0.170 |
Why?
|
| Hemoglobinopathies | 1 | 2019 | 16 | 0.170 |
Why?
|
| DNA, Bacterial | 1 | 2021 | 474 | 0.170 |
Why?
|
| Coinfection | 1 | 2021 | 171 | 0.160 |
Why?
|
| Administration, Oral | 1 | 2021 | 671 | 0.160 |
Why?
|
| Genes, MDR | 1 | 2019 | 6 | 0.160 |
Why?
|
| Enterobacter cloacae | 1 | 2018 | 12 | 0.160 |
Why?
|
| Thyroidectomy | 1 | 2019 | 102 | 0.160 |
Why?
|
| Infant, Newborn | 4 | 2021 | 8116 | 0.160 |
Why?
|
| Cystic Fibrosis | 1 | 2021 | 257 | 0.160 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2019 | 76 | 0.150 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2013 | 361 | 0.150 |
Why?
|
| Genotype | 2 | 2019 | 2539 | 0.150 |
Why?
|
| Immunocompromised Host | 2 | 2022 | 295 | 0.140 |
Why?
|
| Methicillin Resistance | 1 | 2017 | 117 | 0.140 |
Why?
|
| Chronic Disease | 1 | 2021 | 1171 | 0.140 |
Why?
|
| New Zealand | 1 | 2016 | 50 | 0.140 |
Why?
|
| Age Factors | 2 | 2020 | 2808 | 0.130 |
Why?
|
| Sepsis | 2 | 2022 | 476 | 0.130 |
Why?
|
| Australia | 1 | 2016 | 138 | 0.130 |
Why?
|
| Membrane Transport Proteins | 2 | 2019 | 177 | 0.130 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 1414 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2019 | 334 | 0.130 |
Why?
|
| Prevalence | 2 | 2014 | 2409 | 0.120 |
Why?
|
| Genomics | 1 | 2022 | 1474 | 0.120 |
Why?
|
| Diterpenes | 1 | 2014 | 28 | 0.110 |
Why?
|
| Blood | 1 | 2014 | 105 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2018 | 1170 | 0.110 |
Why?
|
| Risk Factors | 2 | 2020 | 10033 | 0.100 |
Why?
|
| Bacterial Proteins | 2 | 2019 | 876 | 0.100 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 424 | 0.100 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 230 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 586 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2020 | 3236 | 0.090 |
Why?
|
| Viral Load | 1 | 2012 | 381 | 0.090 |
Why?
|
| Serotyping | 1 | 2009 | 178 | 0.080 |
Why?
|
| Heart Defects, Congenital | 1 | 2021 | 1803 | 0.080 |
Why?
|
| Pharynx | 1 | 2019 | 64 | 0.080 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2019 | 107 | 0.080 |
Why?
|
| Nevus | 1 | 2008 | 35 | 0.080 |
Why?
|
| Adult | 3 | 2014 | 29091 | 0.080 |
Why?
|
| Antigens, Bacterial | 1 | 2019 | 309 | 0.070 |
Why?
|
| Young Adult | 2 | 2019 | 8870 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2019 | 1022 | 0.060 |
Why?
|
| Pelvis | 1 | 2024 | 68 | 0.050 |
Why?
|
| Clofazimine | 1 | 2021 | 7 | 0.050 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2021 | 25 | 0.050 |
Why?
|
| Animals | 1 | 2022 | 33850 | 0.050 |
Why?
|
| Glycopeptides | 1 | 2020 | 25 | 0.040 |
Why?
|
| beta-Lactams | 1 | 2020 | 50 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 84 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2020 | 254 | 0.040 |
Why?
|
| Salmonella | 1 | 2019 | 28 | 0.040 |
Why?
|
| United States | 1 | 2015 | 10655 | 0.040 |
Why?
|
| Antiporters | 1 | 2019 | 32 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2020 | 202 | 0.040 |
Why?
|
| Enterococcus | 1 | 2019 | 32 | 0.040 |
Why?
|
| Staphylococcus | 1 | 2019 | 70 | 0.040 |
Why?
|
| Pediatrics | 1 | 2008 | 1147 | 0.040 |
Why?
|
| Medical Records | 1 | 2019 | 190 | 0.040 |
Why?
|
| Catheter-Related Infections | 1 | 2020 | 131 | 0.040 |
Why?
|
| Neoplasms | 1 | 2013 | 2759 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2020 | 528 | 0.030 |
Why?
|
| Aged | 1 | 2014 | 19180 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 1081 | 0.030 |
Why?
|
| Echocardiography | 1 | 2020 | 1049 | 0.030 |
Why?
|
| Middle Aged | 1 | 2014 | 26095 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1598 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2019 | 714 | 0.030 |
Why?
|